Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

scPharmaceuticals Q3 EPS $(0.37) Beats $(0.38) Estimate

scPharmaceuticals (NASDAQ:SCPH) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.38) by 2.63 percent. This is a 54.17 percent decrease over losses of $(0.24) per share from
byBenzinga Newsdesk
November 9, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

scPharmaceuticals (NASDAQ:SCPH) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.38) by 2.63 percent. This is a 54.17 percent decrease over losses of $(0.24) per share from the same period last year.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Allogene Therapeutics Launches CAR T Together, A First-Of-Its-Kind Initiative With Oncologists Nationwide, Focused On Accelerating Development And Clinical Trial Recruitment For “Off-The-Shelf” Allogeneic Cell Therapy Investigational Products

By Benzinga Newsdesk
October 11, 8:37 AM
New Survey Focused on Access Limitations of Approved Autologous CAR T Therapies Reveals Only 50% of Eligible Cancer Patients Receive Treatment Increased Patient Demand, Manufacturing Capacity and Time to

ALLO